Short answer: GLP-1 drugs such as Wegovy and Zepbound are now one of the largest specialty drug costs in many employer plans. Employers that keep them covered control the cost with guardrails rather than an exclusion: prior authorization with clinical criteria, reauthorization that requires results, a required lifestyle program, and pharmacy contract terms that pass savings through. What you can actually change depends on how your plan is funded and what your PBM contract says, so start there.
Key takeaways
- Most spend is decided at approval and renewal of the prescription. Clear criteria and reauthorization rules do more than any other single control.
- Your funding sets your options. Fully insured groups choose from the carrier’s menu; self-funded groups write their own rules.
- Many members stop. Persistence is low, so cost modeling has to account for people starting and stopping, not just starting.
- Change carefully. A reduction in coverage needs notice, and a plan for members already on treatment.
Why the cost keeps growing
Use is still rising. Among employers surveyed by the International Foundation of Employee Benefit Plans, GLP-1s made up 10.5% of annual claims in 2025, up from 8.9% the year before. List prices in early 2026 ran about $1,350 a month for Wegovy and about $1,090 for Zepbound, before rebates, and Novo Nordisk has announced a cut to $675 a month for Wegovy and Ozempic from January 1, 2027. In Michigan, Blue Cross Blue Shield of Michigan and Blue Care Network stopped covering the weight-loss drugs for fully insured large groups with their pharmacy coverage from 2025.
For the full set of figures with sources, and the four positions employers take on coverage, see GLP-1 drugs and your health plan. This article is about the controls that sit between full coverage and exclusion.
What the Data Actually Shows About Employer GLP-1 Coverage
Coverage rates depend heavily on employer size, and the figures quoted in trade press usually come from surveys of the largest employers in the country. KFF’s 2025 Employer Health Benefits Survey, published October 22, 2025, breaks it out by headcount.
| Firm Size | Covers GLP-1s for Weight Loss |
|---|---|
| 200–999 workers | 16% |
| 1,000–4,999 workers | 30% |
| 5,000 or more workers | 43% (up from 28% the year before) |
Among firms that do cover these drugs for weight loss, 34% require the employee to meet with a dietitian, case manager or therapist, or take part in a lifestyle program, as a condition of coverage. Utilization also ran ahead of what employers planned for: 44% of firms with 1,000–4,999 workers and 59% of those with 5,000 or more reported that use exceeded expectations.
The Business Group on Health surveyed 105 of its employer members in February and March 2026 and found 67% covering GLP-1s for weight management, but only 72% of those said they were likely to continue that coverage in 2027, and 10% said they likely would not. Most apply standard cost-sharing rather than a special tier (83%), and 87% expect demand to rise as oral GLP-1s reach the market. That membership skews toward very large employers, which is why its coverage rate sits so far above the KFF figure for firms in the hundreds of employees.
The practical read for a Michigan employer in the 25 to 250 range: most of your peers are not covering these drugs for weight loss yet, the ones who do are generally finding utilization higher than forecast, and a meaningful share of the early adopters are now reconsidering. That argues for building the decision on your own claims experience and a written policy you can hold to, rather than on what the market is reported to be doing.
The controls, and what each one costs you
| Control | What it does | The trade-off |
|---|---|---|
| Prior authorization | Approves the drug only when criteria are met, such as a body-mass index threshold with or without a related condition | Administrative friction for members and doctors; criteria must be applied consistently |
| Reauthorization | Renews approval only after a set period with documented results, for example at least 5% of body weight lost after six months | Some members lose coverage mid-treatment; needs clear communication |
| Required lifestyle program | Makes coverage conditional on enrolling in coaching or a weight-management program | Program design must follow HIPAA and ADA wellness rules |
| Quantity and dose limits | Caps supply per fill and prevents early refills | Small savings on its own; best combined with the others |
| Specialty carve-out program | Routes weight-management prescriptions through a vendor that pairs the drug with coaching and monitoring | Adds a per-member fee; results need checking against your own claims |
| Diabetes-only coverage | Keeps coverage for type 2 diabetes and excludes weight-loss use | Not a guardrail but an exclusion; members pay cash for weight-loss use |
Among employers that use utilization management for GLP-1s, prior authorization is close to universal. Reauthorization with a results requirement is where plans differ most, and where most of the long-term savings are.
Your funding decides what you can change
- Fully insured: the carrier’s formulary and riders set your choices. At some sizes you can buy or decline weight-loss coverage; at others the carrier has already decided. Ask what options exist at your group size before renewal.
- Level-funded: GLP-1 use raises expected claims, which feeds your claims fund and stop-loss price. Ask how the carrier prices it into your renewal, and whether you can change coverage mid-contract.
- Self-funded: you write the criteria, choose the carve-out vendor, and negotiate the pharmacy contract. You also carry the risk if use climbs.
Pharmacy contract terms that matter for GLP-1s
- Rebate definition and pass-through. GLP-1s carry large manufacturer rebates. How the contract defines a rebate, and what share reaches the plan, decides your net price.
- Formulary change rights. Whether the PBM can move a drug between tiers or drop it mid-year, and how much notice you get.
- Specialty and mail-order pricing. Where these drugs are dispensed changes the price the plan pays.
- Direct-to-employer options. Some manufacturers now offer pricing to employers through plan administrators, outside the usual PBM route. Compare it to your contract’s net price, not the list price.
See pharmacy benefit consulting, what a PBM is and how a PBM audit works.
What Federal Regulators Found in PBM Pricing
On January 14, 2025 the Federal Trade Commission published its second interim staff report on prescription drug middlemen, examining Caremark, Express Scripts and OptumRx over the period 2017 through 2022. The findings are the clearest public account of how money moves inside a traditional PBM arrangement.
- Across 51 specialty generic drugs, covering 882 National Drug Codes, dispensing revenue at PBM-affiliated pharmacies exceeded estimated acquisition cost by $7.3 billion. The top ten drugs accounted for $6.2 billion of that, or about 85%.
- The three PBMs generated a further $1.4 billion in spread pricing income, the difference between what the plan is billed and what the pharmacy is paid.
- Many specialty generics were marked up by hundreds of percent, and some by thousands.
- In 2021, plan sponsors paid $4.8 billion for these drugs and employees paid $297 million in cost-sharing. Both figures had been climbing at roughly 21% a year in the commercial market since 2017.
- Specialty generic dispensing accounted for about 12% of the parent companies’ total operating income in 2021.
That report concerns specialty generics rather than brand-name GLP-1s, so it is not a direct read on Ozempic or Zepbound spend. It matters for a different reason: it establishes that the contract structure itself, spread versus pass-through, who owns the rebate, whether specialty sits under separate terms, moves real money independent of drug mix. Which is the case for reading your own contract rather than assuming the discount guarantees describe what you are paying. Our PBM audit guide covers what to ask for.
Where the Fiduciary Risk Actually Stands
You may have read that employers are being sued for overpaying for prescription drugs. It is worth being precise about what has and has not happened, because the trade press has been loose with it.
The best-known case, Lewandowski v. Johnson & Johnson, alleged that the plan fiduciaries breached their ERISA duties by failing to ensure prescription drug prices under the health plan were reasonable. The district court dismissed it because the employees could not establish standing, they could not show a concrete injury to themselves. The plaintiffs appealed, and as of September 2026 that appeal is still being briefed at the Third Circuit. A parallel suit against Wells Fargo was dismissed on the same grounds. No court has yet held an employer liable for overpaying for pharmacy benefits.
The duty itself does not depend on those outcomes. ERISA requires plan fiduciaries to act prudently and to pay no more than reasonable fees for plan services, and that obligation applies to the pharmacy benefit whether or not anyone sues. What changed with the Consolidated Appropriations Act is the availability of information: the gag clause prohibition means your PBM can no longer contractually prevent you from seeing cost and claims data, and you now attest annually that no such clause exists in your contracts. Once you are entitled to the data and have certified that you can get it, not having looked is a harder position to defend than it used to be. Our page on the gag clause attestation covers the filing itself.
How reimbursement arrangements change GLP-1 exposure
Employers sometimes ask whether an HRA or ICHRA solves the GLP-1 cost problem. It changes the shape of the exposure rather than removing it, and the distinction matters.
With an ICHRA, employees buy individual coverage and the drug is covered, or not, according to that individual plan’s formulary rather than yours. Your cost is the contribution you set, so a surge in GLP-1 use does not come back to you mid-year. The trade-off is that you no longer control whether the drug is covered, and employees in plans that exclude weight-loss use will discover that themselves. With a QSEHRA, the same logic applies within the IRS limits. With an integrated HRA sitting alongside a group plan, the group plan’s formulary still governs, and the HRA absorbs part of any cost-sharing increase.
Defined contribution converts an unpredictable claims exposure into a budgeted number, which is valuable for a small employer facing specialty drug volatility. It does not make the drugs cheaper, and it moves the coverage decision onto the employee.
Changing coverage without a backlash
- Decide what happens to members already on treatment: a transition period, or continued coverage for current users who meet reauthorization criteria.
- A material reduction in covered services must be communicated to participants, generally within 60 days of adoption, through a summary of material modifications. Most employers give far more notice than that.
- Tell employees about the manufacturers’ self-pay programs if weight-loss use is excluded. Cash purchases do not count toward the plan’s deductible or out-of-pocket maximum.
- Put the rule in the plan document and the summary, and apply it the same way every time, or it becomes an appeals problem.
Helping Employees Check the Cash Price of a Prescription
Employees routinely assume their copay is the lowest available price. For generics and for drugs their plan does not cover, that is often wrong, and two free tools let them check in about a minute.
- GoodRx, enter the drug, dose and quantity and it returns discounted cash prices at pharmacies near them, along with a coupon code the pharmacy applies at the counter.
- SingleCare, works the same way, with a different set of negotiated rates. The two frequently disagree on which pharmacy is cheapest for the same drug, so it is worth checking both.
Neither is insurance. They are discount programs funded by pharmacy network arrangements, free to the employee, and usable whether or not the person has coverage. For a common generic the discounted cash price sometimes lands below the plan copay, and for a drug the plan excludes it may be the only realistic option.
There is one caveat worth putting in front of employees explicitly, because it catches people out: a prescription bought with a discount card is bought outside the plan. It does not run through the PBM, which means it generally does not count toward the deductible or the out-of-pocket maximum, and it does not appear in your claims data. For an employee with modest annual prescription spend that rarely matters. For an employee working toward a deductible they expect to meet, someone with a chronic condition or a planned procedure, paying cash can be the more expensive choice overall even when the sticker price is lower. The rule of thumb to communicate is simple: check the cash price on a one-off generic, and run everything through the plan if you expect to hit your deductible this year.
For GLP-1s specifically, these tools show self-pay pricing rather than a discount off your plan’s rate, and manufacturers also run their own direct-pay channels. Those prices move often enough that we would not print a figure here. The useful point for employers is that employees who lose or never had coverage for these drugs do have a visible cash market, which is worth acknowledging in your communications rather than leaving them to discover it on their own.
Frequently asked questions
Can an employer exclude GLP-1 drugs for weight loss but cover them for diabetes?
Yes, and many plans do exactly that. The exclusion must be stated clearly in the plan document and summary and applied consistently, or it becomes a claims-appeal problem.
What controls work other than excluding the drug outright?
Prior authorization with documented clinical criteria, reauthorization that requires results, a required lifestyle program, quantity limits and specialty carve-out programs. Together they keep the benefit for members who meet the criteria while limiting spend.
How should an employer budget for GLP-1 costs at renewal?
Ask for pharmacy-specific claims detail rather than a single trend number, and model uptake and persistence from your own data. A self-funded or level-funded employer can see actual spend and the number of users; a fully insured employer often cannot.
Will the 2027 price cuts solve the problem?
They help, but most plans pay a net price after rebates rather than list price, and a lower price can increase use. Model the net effect with your own pharmacy data before assuming savings.
Does an ICHRA or QSEHRA reduce GLP-1 costs?
It caps the employer’s cost at the allowance, but does not make the drugs cheaper. Whether the drug is covered then depends on each employee’s individual plan.
Are employers required to cover GLP-1 drugs for weight loss?
We are not aware of a federal or Michigan requirement to cover them for weight loss. Coverage for diabetes follows the plan’s drug list, and on a fully insured plan the carrier’s options may limit what you can choose.
Do we have to notify employees before restricting GLP-1 coverage?
Yes. A material reduction in covered services generally must be communicated within 60 days of adoption, and giving notice well before the change, with a plan for current users, avoids most complaints.
Want to see what GLP-1s are costing your plan?
CFH Insurance Consultants is an independent employee benefits firm, founded in 2007. We are licensed insurance brokers, and for proper coverage of an account we work in teams of five: an account executive, an account manager, a plan analyst, customer service and IT. We will pull your pharmacy claims, show current GLP-1 spend and users, and model what prior authorization, reauthorization or a carve-out would change over two or three years, using aggregated plan data only. Send us your renewal, call 248.370.8853, or book a 30-minute call.
Related reading: GLP-1 drugs and your health plan · Our health and cost strategy
This article is general information, not legal or medical advice. Drug prices and carrier policies change often; confirm current terms with your carrier or PBM.
Unhappy with your current broker? Switch to CFH. Your employees won’t notice. You will.
Also from CFH: Employee Benefits Guidance for Highland Park Businesses · Bridging Employer Health Insurance Gaps: Identifying and Resolving Coverage · Comprehensive Guide to HR Benefits Technology Michigan and Employee Benefits
